VaccinationCompartments after Inactivated Influenza Effector and Memory Immune Longitudinal and Integrative Biomodeling of
暂无分享,去创建一个
Malka | A. Samri | C. Katlama | F. Carrat | S. Kaveri | J. Dimitrov | F. Rozenberg | D. Rousset | O. Launay | B. Combadière | O. Bonduelle | S. Sibéril | Pierre | A. Krivine | A. Curjol | Nora Yahia | M. Louet | Florent Desert | G. Badre | Bricaire | Sylvie van der | Loulergue | François | Tindel | Benhabiles
[1] R. Nussenblatt,et al. Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.
[2] R. Karron,et al. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. , 2012, The Journal of infectious diseases.
[3] J. Oxford,et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans , 2012, Nature Medicine.
[4] Lisa E. Wagar,et al. Humoral and Cell-Mediated Immunity to Pandemic H1N1 Influenza in a Canadian Cohort One Year Post-Pandemic: Implications for Vaccination , 2011, PloS one.
[5] S. Kaveri,et al. Important parameters for evaluation of antibody avidity by immunosorbent assay. , 2011, Analytical biochemistry.
[6] B. Combadière,et al. Transcutaneous and intradermal vaccination , 2011, Human vaccines.
[7] Eva K. Lee,et al. Systems Biology of Seasonal Influenza Vaccination in Humans , 2011, Nature Immunology.
[8] F. Carrat,et al. Field Effectiveness of Pandemic and 2009-2010 Seasonal Vaccines against 2009-2010 A(H1N1) Influenza: Estimations from Surveillance Data in France , 2011, PloS one.
[9] G. Leroux-Roels,et al. Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials , 2011, Clinical and Vaccine Immunology.
[10] F. Ansaldi,et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine , 2011, Human vaccines.
[11] F. Polack,et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes , 2010, Nature Medicine.
[12] R. Cox,et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. , 2010, Vaccine.
[13] Jonathan D. Curtis,et al. Memory CD4+ T cells induce innate responses independently of pathogen , 2010, Nature Medicine.
[14] J. Devaster,et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. , 2010, Vaccine.
[15] C. Wichems,et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.
[16] Libo Dong,et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.
[17] Bjoern Peters,et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population , 2009, Proceedings of the National Academy of Sciences.
[18] F. Marincola,et al. Molecular immune signatures of HIV‐1 vaccines in human PBMCs , 2009, FEBS letters.
[19] Volker Brauer,et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels , 2009, Proceedings of the National Academy of Sciences.
[20] Eva K. Lee,et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.
[21] Bastian R. Angermann,et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.
[22] S. Plotkin,et al. Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] M. Roederer,et al. T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.
[24] Francesco M. Marincola,et al. Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation , 2008, BMC Bioinformatics.
[25] Harry B. Greenberg,et al. Comparison of the Influenza Virus-Specific Effector and Memory B-Cell Responses to Immunization of Children and Adults with Live Attenuated or Inactivated Influenza Virus Vaccines , 2006, Journal of Virology.
[26] Paul G Thomas,et al. Influenza and the challenge for immunology , 2006, Nature Immunology.
[27] Barbara J. Wold,et al. Mining gene expression data by interpreting principal components , 2006, BMC Bioinformatics.
[28] F. Marincola,et al. Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation , 2005, Journal of Translational Medicine.
[29] P. Wright,et al. Role of IgA versus IgG in the Control of Influenza Viral Infection in the Murine Respiratory Tract1 , 2004, The Journal of Immunology.
[30] Andreas Daffertshofer,et al. PCA in studying coordination and variability: a tutorial. , 2004, Clinical biomechanics.
[31] R. Ahmed,et al. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. , 2004, Journal of immunological methods.
[32] A I Saeed,et al. TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.
[33] Martin A. Nowak,et al. Compromised Influenza Virus-Specific CD8+-T-Cell Memory in CD4+-T-Cell-Deficient Mice , 2002, Journal of Virology.
[34] Ka Yee Yeung,et al. Validating clustering for gene expression data , 2001, Bioinform..
[35] B. Arulanandam,et al. IgA Immunodeficiency Leads to Inadequate Th Cell Priming and Increased Susceptibility to Influenza Virus Infection , 2001, The Journal of Immunology.
[36] N. Socci,et al. Leptin-specific patterns of gene expression in white adipose tissue. , 2000, Genes & development.
[37] R. Jaenisch,et al. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells , 1991, The Journal of experimental medicine.
[38] A. McMichael,et al. DECLINING T-CELL IMMUNITY TO INFLUENZA, 1977-82 , 1983, The Lancet.
[39] T. Cate,et al. Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79 , 1983, Journal of clinical microbiology.
[40] A. McMichael,et al. Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.
[41] D. Nelson,et al. Virus specificity of human influenza virus-immune cytotoxic T cells. , 1979, Journal of immunology.
[42] A. McMichael,et al. Influenza virus‐specific cytotoxic T cells in man; induction and properties of the cytotoxic cell , 1978, European journal of immunology.
[43] D. Tyrrell,et al. Immunity to challenge in volunteers vaccinated with an inactivated current or earlier strain of influenza A(H3N2) , 1978, Journal of Hygiene.
[44] A. Monto,et al. Effect of neuraminidase antibody on Hong Kong influenza. , 1973, Lancet.
[45] A. S. Beare,et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.